Susan G. Komen

@SusanGKomen · Dallas, Texas · joined 11 Sep 2008

A force united by a promise to end breast cancer, funding groundbreaking research, community health & advocacy programs globally. https://t.co/f6ngGND7es

104 011Followers

3 701Following

22 199Posts total

20.5KViews on collected posts

Latest posts

Susan G. Komen@SusanGKomen3 Jun

Marni Blair McClure, MD, PhD, @cncurtis, @AllisonKurian, @caswell_jin Laura Burns Amin, MD, Mariana Chavez MacGregor, MD, @shgiordano Harikrishna Nakshatri, PhD #ASCO26 @ASCO https://t.co/guNjFTuoAG 1.2K views · 3 likes · 0 reposts · 1 replies Open on X →

Susan G. Komen@SusanGKomen3 Jun

@NTungMD @marijasullivan, Mariana Chavez MacGregor, MD @anaelisalohman1 #ASCO26 @ASCO https://t.co/ZqCK6YLCnr 469 views · 1 likes · 0 reposts · 0 replies Open on X →

Susan G. Komen@SusanGKomen3 Jun

Thrilled to see many Komen-supported grantees & posters at #ASCO26. Each reflects scientific progress and the dedication of researchers improving outcomes for people impacted by breast cancer. Proud to support science, moving us closer to a world without breast cancer. @ASCO 1.3K views · 2 likes · 0 reposts · 1 replies Open on X →

Susan G. Komen@SusanGKomen2 Jun

🧬 Sara Hurvitz, MD presents VIKTORIA-1 at #ASCO26: In HR+/HER2- PIK3CA-mutant breast cancer after CDK4/6i, gedatolisib + fulvestrant (with or without palbociclib) doubled progression-free survival vs standard of care (11.1 vs 5.6 months). 🎯 @ASCO https://t.co/tGj6Qorbo6 920 views · 11 likes · 6 reposts · 0 replies Open on X →

Susan G. Komen@SusanGKomen2 Jun

🧬 Francois Bidard, MD, Ph.D. presents SERENA-6 at #ASCO26: Switching to camizestrant + CDK4/6i when ESR1 mutations emerge during first-line therapy improved outcomes through 2 lines of treatment in HR+/HER2- advanced breast cancer @ASCO https://t.co/Iod25y4cyH 576 views · 3 likes · 1 reposts · 0 replies Open on X →

Susan G. Komen@SusanGKomen2 Jun

GLP-1 use is rising but what about #breastcancer risk? Long term safety matters. At #ASCO26, Elizabeth Susan McDonald, MD, PhD reported GLP-1 treatment was associated with lower BC incidence in women, but clinical trials are needed to confirm a true risk reduction effect. @ASCO 1.2K views · 11 likes · 4 reposts · 0 replies Open on X →

Susan G. Komen@SusanGKomen2 Jun

PANKU-Breast02 phase 3 trial: iza-bren vs chemo in pre-treated metastatic TNBC. Jiong Wu, MD, PhD reported that patients had improved overall survival & stayed progression-free longer w/ manageable side effects, suggesting iza-bren could become a new standard option @ASCO #ASCO26 647 views · 5 likes · 4 reposts · 0 replies Open on X →

Susan G. Komen@SusanGKomen11 Dec 2024

Today at @SABCSSanAntonio, we are proud to honor 5 exceptional leaders for their groundbreaking work in advancing our understanding of breast cancer risk, metastasis, personalized treatments & education. Read more: https://t.co/F1xZXav22R #SABCS24 https://t.co/rQPQSTOctR

14.1K views · 23 likes · 7 reposts · 2 replies Open on X →

Growth & engagement

How the posts we collected actually performed: views and reaction rate post by post, what the audience did with them, and where the follower count goes.

Views per post

14.1K11 Dec

6472 Jun

1.2K

576

920

1.3K3 Jun

469

1.2K

Last 8 collected posts, oldest on the left. The scale is logarithmic: one post can outrun the rest a hundred times over.

Engagement rate per post

0.28%11 Dec

1.39%2 Jun

1.27%

0.69%

1.85%

0.23%3 Jun

0.21%

0.33%

Reactions — likes, reposts, replies and quotes — divided by views.

What the audience does

Likes59.6%59 in total

Reposts22.2%22 in total

Replies4.0%4 in total

Quotes8.1%8 in total

Bookmarks6.1%6 in total

Share of every reaction we collected for this account. Replies mean argument, reposts mean endorsement, bookmarks mean the post was worth keeping.

The follower curve appears once this account has two daily snapshots — we take one a day, and this one is on its first.

Latest posts

Growth & engagement

Views per post

Engagement rate per post

What the audience does

Similar accounts